Quest Diagnostics Inc. reported its financial results for the first quarter of 2025, surpassing analyst expectations. The company's adjusted diluted earnings per share (EPS) reached $2.21, exceeding the estimated $2.15. Revenue for the quarter was $2.65 billion, also beating the anticipated $2.63 billion and representing a 12.1% increase from the same period in 2024. Reported diluted EPS rose 12.8% year-over-year to $1.94, while adjusted diluted EPS increased 8.3%. The earnings beat was attributed to a rebound in demand in March following a slump earlier in the quarter. Quest Diagnostics reaffirmed its revenue and adjusted diluted EPS guidance for the full year 2025. Following the earnings release, Quest Diagnostics' stock (NYSE: DGX) saw a pre-market increase of 3.2%.